Metabolic Complications of HIV and Antiretroviral Therapy: Dyslipidemia, Insulin Resistance, and Cardiovascular Disease

  • Authors: Judith S. Currier, MD, MSc; Risa Hoffman, MD, MPH (More Info)
  • Editors in Chief: Joseph J. Eron, Jr., MD; Daniel R. Kuritzkes, MD
  • Last Reviewed: 10/10/18 (What's New)

Summary

  • Traditional risk factors for dyslipidemia remain relevant to HIV-infected patients
    • These include older age, male sex, family history, poor diet, increased BMI, and sedentary lifestyle
  • All HIV-infected patients should have fasting lipids evaluated at entry to care and before ART initiation[Aberg 2014]
      • PIs and Dyslipidemia
        NRTIs and Dyslipidemia
          NNRTIs and Dyslipidemia
            Integrase Inhibitors, Maraviroc, and Dyslipidemia

            Action required

            Keywords: Dyslipidemia, Treatment Complications

            ©2020 Clinical Care Options, LLC. All Rights Reserved.

            The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.